The Effect of E-Health Management on Gestational Diabetes Control
Randomized Controlled Trail of e-Health Management for Women With Prior Gestational Diabetes Mellitus
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Background: Women with previous gestational diabetes mellitus are at increased risk for developing type2 diabetes mellitus or metabolic syndrome in their later life. Infants of mothers with GDM are more susceptible to stillbirth and more serious health concerns. With limited time for visits and the predicament of education, applying web-based intervention has become a convenient tool for health management.
Objectives: The approved project aimed to develop an e-heath management platform(eHMP) for women with high risk of gestational diabetes mellitus (GDM) and to evaluate the longitudinal effects between groups of eHMP intervention. The eHMP integrate GDM health care knowledge, self-awareness of health, self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends); participation in discussions or browsing forums; healthy lifestyle guidance and counseling; reminder systems, a token system of earning points in exchange for prizes.
Methods: Pregnant women aged 18-45 years with high risk of metabolic syndrome who have a singleton pregnancy, are eligible to participate in this study. Women who agree to participate in the study will be given a participant information sheet and consent form. Participants will be recruited from the Pregnancy diabetes Clinic, at Chang Gung memorial hospital and introduced to the eHMP using the mobile phone in the clinic. Participants will also be given the URL to access to the program and they can learn the modules at home by using their home PCs, mobile phones, or tablets. They were followed up for three times: 28 weeks' gestation, 36-40 weeks' gestation and 6-12 weeks postpartum. SPSS version 20.0 software was used to compile and analyze the research data, including questionnaires and blood test for metabolic index.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Taipei, Taiwan, 10507
- Chang Gung Memorail Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Pregnant women (pre-pregnancy body mass index ≧ 24) must meet at least one of the following conditions and agree to be interviewed:
- Age over 34 years old;
- Ever had giant infant delivery (weight ≧ 4.5 kg);
- Previous diagnosed with gestational diabetes ;
- Family history of diabetes.
Exclusion Criteria:
- Pre-existing diabetes (types 1 and 2);
- Unable to write and understand Chinese;
- Subject has cognitive impairment;
- Subject has intellectual disability or mental illness;
- Dependent on medical care (eg, anti-depressants, or any psychiatric medication)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: eHMP experimental group
The experimental group received health management support and counseling,including:
|
Pregnant women who agree to take part will be assigned to a group: experimental group and control group.
The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
Muut nimet:
|
|
Ei väliintuloa: Control group
only received usual care
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change of Triglyceride Level
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal triglyceride was <150 mg/dl; ≥150mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Fasting Blood Glucose (FBG) Level
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal FBG was < 100 mg/dl; ≥100mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of high-density lipoprotein cholesterol (HDL) level
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal HDL was ≥50 mg/dl; <50mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Cholesterol level
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal Cholesterol was < 200 mg/dl; ≥200mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of systolic blood pressure
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
Normal systolic blood pressure was <130mmHg; ≥130mmHg was abnormal.
Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of diastolic blood pressure
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
Normal diastolic blood pressure was <85mmHg; ≥85mmHg was abnormal.
Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of body weight
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
Women's weight following as assessed using calibrated digital scales
|
Change from Baseline at 6-12 weeks after delivery
|
|
Newborn baby weight
Aikaikkuna: at birth
|
Newborn baby weight in normal range (>2500g - <4500g) - dichotomous outcome Yes/No assessed using calibrated digital scales.
|
at birth
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change of Pregnancy Physical Activity Assessment
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
There are 12 items in this questionnaire, including two dimensions: exercise and inactivity.
Exercise dimension contained four items to assess the type of physical activity, intensity, duration, frequency during pregnancy.
At least 3 days per week, and each time at least 20-30 minutes, counted as regular exercise (dichotomous outcome Yes/No assessed).
Inactivity dimension contained 8 items, dichotomous outcome Yes/No assessed (score 0-8), higher values represent an inactivity lifestyle.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Dietary Behavioral Characteristics Scale
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
The instrument is 17-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always).
It including two dimensions and each scale range as: balanced diet (5 items, scale range 5-25) and diet control behavior (12 items, scale range 12-60).
Higher values represent a better maternal dietary patterns during pregnancy.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Health Promotion Scale
Aikaikkuna: Change from Baseline at 6-12 weeks after delivery
|
The instrument is 40-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always).
It including six dimensions and each scale range as: social-support (6 items, scale range 6-30), life-appreciation (8 items, scale range 8-40), health-responsibility (8 items, scale range 8-40), stress-management (9 items, scale range 9-45), nutritional behaviors (5 items, scale range 5-25) and exercise behaviors (4 items, scale range 4-20).
The total score was 40 to 200, higher values represent a better health promotion lifestyle.
|
Change from Baseline at 6-12 weeks after delivery
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Mei-Chen Su, Dr., Chang Gung Memorial Hospital
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 105-4129C
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .